Skip to content
10-Q

Quarterly Report

AXSOME THERAPEUTICS, INC. AXSM

0001193125-26-204274

← back to feed
Filed
May 4, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 27, 2026 51.46M sh
Shares Diluted Q1 2026 · Mar 31, 2026 51.2M sh
Shares Diluted Q1 2026 · Mar 31, 2025 48.87M sh
Capex Q1 2026 · Mar 31, 2026 $121K
Capex Q1 2026 · Mar 31, 2025 $338K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$20.7M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$43.38M
Long Term Debt Q1 2026 · Mar 31, 2026 $117.85M
Long Term Debt Q1 2026 · Dec 31, 2025 $117.75M
Short Term Debt Q1 2026 · Mar 31, 2026 $70M
Short Term Debt Q1 2026 · Dec 31, 2025 $70M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $305.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $322.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $54.59M
Stockholders Equity Q1 2026 · Dec 31, 2025 $88.3M
Stockholders Equity Q1 2026 · Mar 31, 2025 $53.21M
Stockholders Equity Q1 2026 · Dec 31, 2024 $57.02M
Current Liabilities Q1 2026 · Mar 31, 2026 $439.21M
Current Liabilities Q1 2026 · Dec 31, 2025 $378.84M
Total Liabilities Q1 2026 · Mar 31, 2026 $659.02M
Total Liabilities Q1 2026 · Dec 31, 2025 $601.51M
Current Assets Q1 2026 · Mar 31, 2026 $611.21M
Current Assets Q1 2026 · Dec 31, 2025 $588.99M
Total Assets Q1 2026 · Mar 31, 2026 $713.61M
Total Assets Q1 2026 · Dec 31, 2025 $689.81M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.26
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.22
Eps Basic Q1 2026 · Mar 31, 2026 −$1.26
Eps Basic Q1 2026 · Mar 31, 2025 −$1.22
Sga Expense Q1 2026 · Mar 31, 2026 $185M
Sga Expense Q1 2026 · Mar 31, 2025 $120.79M
Rd Expense Q1 2026 · Mar 31, 2026 $52.68M
Rd Expense Q1 2026 · Mar 31, 2025 $44.79M
Net Income Q1 2026 · Mar 31, 2026 −$64.54M
Net Income Q1 2026 · Mar 31, 2025 −$59.41M
Operating Income Q1 2026 · Mar 31, 2026 −$63.36M
Operating Income Q1 2026 · Mar 31, 2025 −$56.98M
Revenue Q1 2026 · Mar 31, 2026 $191.2M
Revenue Q1 2026 · Mar 31, 2025 $121.46M